Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-04
2011-01-04
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S315000, C514S183000
Reexamination Certificate
active
07863242
ABSTRACT:
The present invention relates to the downregulation of surface receptor CCR5 expression through manipulation of the cell cycle in activated lymphocytes by administering a composition that arrests the G1 phase of the cell cycle, thereby reducing receptor sites for entry of HIV into T cells, and thus, the effects of HIV. Further, compositions are disclosed that include at least one G1 phase arresting agent and at least one antiviral agent, wherein the combination of agents synergistically enhances the activity of the antiviral agent.
REFERENCES:
patent: 5962462 (1999-10-01), Mills et al.
patent: 5994136 (1999-11-01), Naldini
patent: 6013644 (2000-01-01), Mills et al.
patent: 6098780 (2000-08-01), Kelly et al.
patent: 6150530 (2000-11-01), Kempf et al.
patent: 2003/0060457 (2003-03-01), Schaffer et al.
patent: 2003/0099944 (2003-05-01), Schaffer et al.
patent: 2006/0099170 (2006-05-01), Redfield et al.
patent: WO-94/05300 (1994-03-01), None
patent: WO98/25604 (1997-12-01), None
patent: WO-99/47146 (1999-09-01), None
patent: WO-99/48504 (1999-09-01), None
patent: WO00/51610 (2000-03-01), None
patent: WO 02/053096 (2002-07-01), None
patent: WO 02/056902 (2002-07-01), None
patent: WO 02/062123 (2002-08-01), None
patent: WO03/027671 (2002-09-01), None
patent: WO02100401 (2002-12-01), None
patent: WO 03/053468 (2003-07-01), None
Lori, et al. “Strucutured treatment interruptions as a potential alternative therapeutic regimen”, Journal of Antimicrobial Chaemotherapy (2002) 50, 155-160.
Spada, et al. “An Evaluation of Antiretrovial Therapy Associated with α-Tocopherol” Clin. Chem.. Lab. Med (2002) 40(5), 456-459.
Paton, et al., “Hydroxychloroquine, hydroxycarbamide and didanosine as economic treatment for HIV-1” The Lancet, (2002) V.359, 1667.
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999)Proc. Natl. Acad. Sci. USA96, 5698-5703.
Baba, M., Imai, T., Yoshida, T. & Yoshie, O. (1996)Int. J. Cancer66, 124-129.
Bleul, C., Wu, L., Hoxie, J., Springer, T. & Mackay, C. (1997)Proc. Natl. Acad. Sci. USA94, 1925-1930.
Bjornal, A., Sonnerborg, A., Tscherning, C., Albert, J. & Fenyo, E. (1999)AIDS Res. Hum. Retroviruses15, 647-653.
Calabrese, L., Lederman, M., Spritzler, J., Coombs, R., Fox, L., Schock, B., Yen-Lieberman, B., Johnson, R., Mildvan, D. & Parekh, N. (2002)J. Acquired Immune Defic. Syndr. 29, 356-362.
Cocchi, F., DeVico, A., Garzino-Demo, A., Arya, S., Gallo, R. & Lusso, P. (1995)Science270, 1811-1815.
Castedo, et al., (2002) EMBO Journal, 21 (15) pp. 4070-4080.
Dybul, M., Fauci, A., Barlett, J., Kaplan, J. & Pau, A. (2002)Ann. Intern. Med. 137, 381-433.
Essex, M. (1999)Adv. Virus Res. 53, 71-88.
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002)Nat. Med. 8, 128-135.
Heredia, A; Amoroso, A; Davis, C.; Le, N.; Readon, E.; Klingebiel, E.; Gallo, R.C; and Redfield R.R. (2003)Proc. Natl. Acad. Sci. USA, 100 (18) 10411-10416.
Heredia, A., Davis, C., Amoroso, A., Dominique, J., Le, N., Klingebiel, E., Reardon, E., Zella, D. & Redfield, R. (2003)Proc. Natl. Acad. Sci. USA100, 4179-4184.
Heredia, A. et al, Journal of Human Virology 3(5): 248 (Sep.-Oct. 2000).
Kahan, B. & Camardo, J. (2001)Transplantation72, 1181-1193.
Kinter, A., Poli, G., Fox, L., Hardy, E. & Fauci, A. (1995)J. Immunol. 154, 2448-2459.
Lane, B., Markovitz, D., Woodford, N., Rochford, R., Strieter, R. & Coffey, M. (1999)J. Immunol. 163, 3653-3661.
Levine, B., Mosca, J., Riley, J., Carroll, R. G., Vahey, M. T., Jagodzinski, L. L., Wagner, K. F., Mayers, D. L., Burke, D. S., Weislow, O. S., et al. (1996)Science272, 1939-1943.
Liu, R., Paxton, W., Choe, S., Ceradini, D., Martin, S., Horuk, R., MacDonald, M., Stuhlmann, H., Koup, R. & Landau, N. (1996)Cell86, 367-377.
Lin, Y.-L., Mettling, C., Portales, P., Reynes, J., Clot, J. & Corbeau, P. (2002)Proc. Natl. Acad. Sci. USA99, 15590-15595.
Loetscher, P., Seitz, M., Baggiolini, M. & Moser, B. (1996)J. Exp. Med. 184, 569-577.
Lori, F., Malykh, A., Cara, A., Sun, D., Weinstein, J. N., Lisziewicz, J. & Gallo, R. C. (1994)Science266, 801-805.
Morice, et al. (1993)J. Biological Chemistry, vol. 268 (5) pp. 3734-3738.
Perno, C. & Yarchoan, R. (1993) inCurrent Protocols in Immunology, eds. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M. & Strober, W. (Wiley, New York), pp. 12.4.1-12.4.11.
Poli, G. & Fauci, A. (1993) inCurrent Protocols in Immunology, eds. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M. & Strober, W. (Wiley, New York), pp. 12.3.1-12.3.7.
Poon, M., Badimon, J. & Fuster, V. (2002)Lancet359, 619-622.
Reeves J et al., (2002) PNAS 99: 16249-16254.
Rizzardi, G., Harari, A., Capiluppi, B., Tambussi, G., Ellefsen, K., Ciuffreda, D., Champagne, P., Bart, P., Chave, J., Lazzarin, A. & Pantaleo, G. (2002)Clin. Invest. 109, 681-688.
Roy, J., Sébastien, J., Fortin, J. & Tremblay, M. (2002)Antimicrob. Agents Chemother. 46, 3447-3455.
Sehgal, S.-N. (1998)Clin. Biochem. 31, 335-340.
Simmons, G., Clapham, P., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser, R., Wells, T. N. & Proudfoot, A. E. (1997)Science276, 276-279.
Spina, C., Guatelli, J. & Richman, D. (1995)J. Virol. 69, 2977-2988.
Strizki, J., Xu, S., Wagner, N., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., et al. (2001)Proc. Natl. Sci. USA98, 12718-12723.
Trkola, A., Kuhmann, S., Strizki, J., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., et al. (2002)Proc. Natl. Acad. Sci. USA99, 395-400.
Terada N, et al., (1993) J of Cellular Phys., 154 pp. 7-15.
Ullman, K., Northrop, J., Verweij, C. & Crabtree, G. (1990)Annu. Rev. Immunol. 8, 421-452.
Ward, S., Bacon, K. & Westick, J. (1998)Immunity9, 1-11.
Weissman, D., Dybul, M., Daucher, M., Davey, R., Walker, R. & Kovacs, J. (2000)J. Infect. Dis. 181, 933-938.
Willey, R., Smith, D., Lasky, L., Theodore, T., Earl, P., Moss, B., Capon, D. & Martin, M. (1988)J. Virol. 62, 139-147.
Zack, J., Arrigo, S., Weitsman, S., Go, A., Haislip, A. & Chen, I. (1990)Cell61, 213-222.
Zella, D., Riva, A., Weichold, F., Reitz, M. & Gerna, G. (1998)Immunol. Lett. 62, 45-49.
Andrieu, et al. “Results of a 2-year exploratory study with cyclosporin a in human immunodeficiency virus infection.” (1998) inAutoimmune Aspects of HIV Infection, eds. (R. Soc. Med. Services, London), pp. 191-194.
Sherman DS. Et al, “Hydroxurea in the treatment of HIV infection” AIDS Reader, vol. 9, No. 1, Jan. 1999, pp. 18-19 and 23-24.
Kootstra NA, et al. “Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transpro in primary macrophages arrested in early G1 phase of the cell cycle” Journal of Virology, vol. 74, No. 4, Feb. 2000, pp. 1712-1717.
Wang et al, “Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors” Journal of Virology, The American Society for Microbiology, vol. 75, No. 16. Aug. 2001, pp. 7266-7279.
Amoroso Anthony
Davis Charles E.
Heredia Alonso
Redfield Robert R.
Fuierer Marianne
Moore & Van Allen PLLC
University of Maryland Baltimore
Wang Shengjun
LandOfFree
Compositions for down-regulation of CCR5 expression and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for down-regulation of CCR5 expression and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for down-regulation of CCR5 expression and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717036